AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04720131
Drug: apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle) The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group.~The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage.
Trial: NCT03877991
Drug: CBD-sesame oil capsule
RxNorm normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A capsule containing cannabidiol dissolved in sesame oil and surfactant vehicle.
Trial: NCT06633718
Drug: Meropenem and Pralurbactam
RxNorm normalized name: meropenem and vaborbactam
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3g，q8h，120min infusion
Trial: NCT06633718
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mL，q8h，60min infusion
Trial: NCT06633718
Drug: Ceftazidime-avibactam
RxNorm normalized name: avibactam
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5g，q8h，120min infusion
Trial: NCT06633718
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.915g，q8h，60min infusion
Trial: NCT04842565
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (200mg ivdrip D1 Q3W)
Trial: NCT05903456
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ronvastinib is an orally administered multi-receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors, such as VEGF-1, VEGF-2, and VEGF-3, in addition to inhibiting other pro-angiogenic and oncogenic signaling pathways associated with tumor proliferation ，has been approved as a first-line treatment for liver cancer
Trial: NCT05903456
Drug: Icaritin soft capsules
RxNorm normalized name: Icaritin
DrugBank: Icaritin (DB12672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icaritin soft capsule is a flavonoid compound extracted from traditional Chinese medicinal materials. It is a new type of small molecule immunomodulator. It is a 1.2 class of innovative Chinese medicine with global independent intellectual property rights. By inhibiting inflammatory signaling pathway and reducing the release of inflammatory factors, the immune microenvironment can be regulated to play an anti-tumor role. At present, it has been approved for first-line treatment of advanced liver cancer, with good efficacy and safety.
Trial: NCT04602715
Drug: MET-2
RxNorm normalized name: Met
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.
Trial: NCT06632561
Drug: Empagliflozin 10 mg
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin (a sodium-glucose cotransporter-2 inhibitor) 10 mg one tablet daily dose for 6 months
Trial: NCT05873712
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05873712
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00006267
Drug: rubitecan
RxNorm normalized name: Rubitecan
DrugBank: Rubitecan (DB06159)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06457958
Drug: Sevoflurane Group
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Sevoflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Sevoflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR.
Trial: NCT04758975
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VENETOCLAX: Ramp-up than 400 mg QD
Trial: NCT04758975
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2
Trial: NCT04758975
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IBRUTINIB 420 mg QD
Trial: NCT06361979
Drug: SHR-A1811
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1811: intravenous
Trial: NCT06361979
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab:intravenous
Trial: NCT06457958
Drug: Desflurane Group
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Desflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Desflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR.
Trial: NCT06374758
Drug: bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Same as above, it is the same intervetion
Trial: NCT04521582
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The facility-based community health worker will receive protocol-driven training to initiate amlodipine for hypertensive patients. These patients will receive lifestyle counseling by Female Community Health Volunteer through home visits (5 times \[including baseline and end of the study\] in the active municipality and 3 times \[including baseline and end of the study\] in the control municipality).
Trial: NCT05241028
Drug: Ensartinib
RxNorm normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
Trial: NCT04913805
Drug: Potassium Nitrate
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle
Trial: NCT00496535
Drug: TNFerade biologic
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06240520
Drug: Panobinostat 20 MG Oral Capsule
RxNorm normalized name: panobinostat 20 MG Oral Capsule
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat 20mg will be administered once orally
Trial: NCT06240520
Drug: Pyrimethamine 200mg Oral Tablet
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrimethamine 200mg will be administered once orally
Trial: NCT06240520
Drug: Lenalidomide 25 MG Oral Capsule
RxNorm normalized name: Lenalidomide 25 mg oral capsule
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 25mg will be administered once orally
Trial: NCT04220931
Drug: botulinum toxin injection
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
Trial: NCT05644600
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The subjects will be administered Nintedanib soft capsules single oral dose in the morning of Day 1 in fasted state.
Trial: NCT05366764
Drug: Salbutamol or levosalbutamol
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Levosalbutamol (DB13139)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metered dose inhaler
Trial: NCT06273839
Drug: Tafamidis 61 mg free acid tablet (Test 1)
RxNorm normalized name: tafamidis 61 MG
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tafamidis 61 mg free acid tablet (Test 1)
Trial: NCT06273839
Drug: Tafamidis 70 mg free acid tablet (Test 1)
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tafamidis 61 mg free acid tablet (Test 1)
Trial: NCT06273839
Drug: Tafamidis 61 mg free acid capsule (Reference)
RxNorm normalized name: tafamidis 61 MG
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tafamidis 61 mg free acid capsule (Reference)
Trial: NCT05994001
Drug: LM-302
RxNorm normalized name: LM-030
DrugBank: LM-030 (DB18283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LM-302 :ClAUDIN 18.2-ADC
Trial: NCT05522985
Drug: Triprilimab combined with TP
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
Trial: NCT05494645
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal bupivicaine
Trial: NCT05494645
Drug: Peripheral Nerve Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peripheral nerve block without Exparel
Trial: NCT04565925
Drug: Sildenafil Citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 20mg TID for 4 weeks
Trial: NCT05210374
Drug: Copper Gluconate
RxNorm normalized name: Copper Gluconate
DrugBank: Copper gluconate (DB11246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To be taken orally (PO), 5.2mg/m2/day daily in the PM, rounded~for pill size (max 9mg/day) To be administered day 1-7~Lead-in week and day 1-28 cycles Cycle length: 28~days, maximum 12 cycles
Trial: NCT06344936
Drug: HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice
Trial: NCT04474990
Drug: Tradipitant
RxNorm normalized name: Tradipitant
DrugBank: Tradipitant (DB12580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK-1 Receptor antagonist
Trial: NCT04889287
Drug: Elinzanetant (BAY3427080)
RxNorm normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily over 12 days
Trial: NCT04475835
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 4 hours after PCI. A prolonged infusion of 0.2 mg/kg/h for ≤20h could be considered at the operator's discretion. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.30 mg/kg of bivalirudin should be administered.
Trial: NCT06132932
Drug: WX390
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.
Trial: NCT04300140
Drug: Batiraxcept
RxNorm normalized name: Batiraxcept
DrugBank: Batiraxcept (DB17522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batiraxcept is experimental drug
Trial: NCT04300140
Drug: Cabozantinib (Cabo)
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib is standard of care as monotherapy and in combination with nivolumab in ccRCC
Trial: NCT04300140
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is standard of care in the first line treatment of ccRCC
Trial: NCT05669963
Drug: lactoferrin
RxNorm normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month.
Trial: NCT05044988
Drug: HS-10342
RxNorm normalized name: sodium chloride 0.00342 MEQ/MG
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HS-10342 tablet once daily from Day 1 to 21 of a 28-day cycle
Trial: NCT05156905
Drug: Cirmtuzumab
RxNorm normalized name: Cirmtuzumab
DrugBank: Zilovertamab (DB18403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cirmtuzumab will be given in combination with docetaxel.
Trial: NCT04709211
Drug: bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine
Trial: NCT05743179
Drug: Zoledronate
RxNorm normalized name: Zoledronate
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aclasta Solution for Infusion 5mg/100ml (zoledronic acid)
Trial: NCT05575167
Drug: Zoledronate or Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: infusion (for zoledronate) or oral digestion (for alendronate)
Trial: NCT06389799
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: selective fibroblast growth factor receptor (FGFR) inhibitor, oral tablet
Trial: NCT06389799
Drug: Retifanlimab
RxNorm normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor, Intravenous infusion
Trial: NCT05713851
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: dapagliflozin is given for 21 days vs standard of care
Trial: NCT05725837
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
Trial: NCT06439914
Drug: [89Zr]Zr-DFO-emapalumab
DrugBank: Emapalumab (DB14724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotracer \[89Zr\]Zr-DFO-emapalumab administration followed by 3 PET Scans (day 0, day 1 and day 3-5) within 14 days of starting immunotherapy and repeated once 25-45 days after immunotherapy started
Trial: NCT04781192
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intra-Venous(IV) once every 28 days (approximately every 4 weeks \[q4w\])
Trial: NCT04781192
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral once per day, Days 1 - 21 every 28 days
Trial: NCT05913089
Drug: TQB2450 injection + Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Chemotherapy is a systematic treatment that kill fast growing cells.
Trial: NCT05913089
Drug: TQB2450 injection + Anlotinib Hydrochloride Capsule
RxNorm normalized name: terbinafine
DrugBank: Anlotinib (DB11885)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Trial: NCT06182761
Drug: Sunvozertinib combination with Anlotinib
RxNorm normalized name: miconazole
DrugBank: Anlotinib (DB11885)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sunvozertinib 300 mg once daily (QD) with Anlotinib 12mg once daily （QD in Day 1-14） ，21 days in one cycle.
Trial: NCT04735861
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg iv. q3w, up to 2 years.
Trial: NCT04735861
Drug: Bevacizumab Biosimilar IBI305
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
Trial: NCT04614246
Drug: Elagolix
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT06585462
Drug: AMG 513
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 513 will be administered by SC or IV injection.
Trial: NCT05753501
Drug: ABBV-101
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral:Tablet
Trial: NCT05903014
Drug: n-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: we give 3600 mg n-acetylcysteine divided twice a day, for 12 weeks
Trial: NCT05353010
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 5mg (1 mg \* 5 capsules)
Trial: NCT05353010
Drug: IN-A001(Tegoprazan)
RxNorm normalized name: IN-A001
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN-A001 50mg(Tegoprazan 50mg\* 1 tablet)
Trial: NCT05353010
Drug: IN-A001(Tegoprazan) + Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IN-A001 50mg(Tegoprazan 50mg\*1 tablet) and Tacrolimus 5mg(1mg \* 5capsules)
Trial: NCT05191017
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide
Trial: NCT00002282
Drug: Clotrimazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002282
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04641078
Drug: Darolutamide
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg BID
Trial: NCT04791878
Drug: Mesenchymal stem cells
RxNorm normalized name: Placental Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells at baseline and again after 3 months if not completely healed
Trial: NCT05347212
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV
Trial: NCT05347212
Drug: Relatlimab
RxNorm normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT05779423
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monoclonal antibody administered through intravenous infusion
Trial: NCT05779423
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monoclonal antibody administered through intravenous infusion
Trial: NCT05475886
Drug: Hydroxyethyl starch 130/0.4
RxNorm normalized name: Hydroxyethyl starch 130/0.4
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An initial infusion dose of 500 ml 6% Hydroxyethyl starch (130/0.4) coload simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 100 ml according to the responses of previous patients according to the up-down sequential allocation.
Trial: NCT06251492
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab 20mg/kg IV Q3W for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression
Trial: NCT06633068
Drug: Adding perineural Nalbuphine to Bupivacaine in superficial cervical nerve block
RxNorm normalized name: ACS22Q55 NERVE BLOCK KIT
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries
Trial: NCT04820530
Drug: Iptacopan (LNP023)
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral